Navigation Links
New Generation - Medicinal Products

Medicinal product is always the result of a subtle marriage between a compound (the active substance which treats a patient) and an appropriate excipient// (a neutral substance in which the active substance is incorporated so that it can be absorbed by the body). Thus the necessary tablet, capsule or syrup is obtained. But what would happen if biodegradable materials were used instead of these neutral excipients? This was already possible with some active substances, and can now be applied to many others!

The team led by Didier Bourissou in the Laboratory for Fundamental and Applied Heterochemistry (CNRS/University Toulouse 3), has indeed managed to develop a novel synthetic process for these materials, which significantly increases their diversity.

Some biodegradable polymers such as polyesters have already been employed as excipients in pharmacology. But this was only possible when they were mixed with certain active substances such as anticancer drugs or growth hormones. And in the field of surgery, the secret of absorbable sutures does indeed reside in the use of these same polyesters.

What are the principles underlying these "new generation" drugs? The biodegradable excipient containing the active substance can take the form of an implant – a 1 cm-long rod about one millimeter in diameter – which is inserted just under the skin. This procedure is performed by a doctor and only takes a few minutes. The specificity of these polyesters is that they can be hydrolyzed; in other words, broken down by water, which is unlucky for them, as our bodies are full of this substance. Thus the excipient gradually breaks down, over a week, a month or three months, depending on its type, releasing the active substance it contains.

Hence the major advantage of the technique: biodegradable excipients enable the controlled administration of sustained-release drugs. This is of considerable benefit in the setting of chronic diseases, a s it avoids frequent, repeated intakes of medicines. Another positive point is that this method reduces side effects; by circumventing the digestive tract, the active substance passes directly into the bloodstream. Thus it is also possible to reduce the quantity of drug administered, as there is no longer any need to allow for its partial destruction as it passes through the digestive tract.

In view of these advantages, why can the technique not be extended to a broader range of active substances? Because, until now, we only knew how to make these biodegradable polymers using two monomers (the basic components of polymers), lactide and glycolide. It is rather like making a bead necklace when only green and red beads are available. And in the same way that such a two-colored necklace would not match all outfits, so the polyesters obtained cannot be combined with just any active substance. Without accounting for the fact that when using these little reactive lactide and glycolide monomers, industrial preparation of the polymers requires lengthy reaction times at high temperatures (e.g. several hours at 140°C-160°C).

This is where Didier Bourissou's team same up with the idea of changing the recipe and ingredients in order to facilitate access to these polyesters and increase their diversity. Many tests later, they achieved their goal. In collaboration with Isochem, they have developed a new synthetic process for these polymers. This involves new elementary building blocks, the O-carboxy anhydrides, which are much more reactive (i.e. more beads for our necklace), so that the polyesters can be prepared under much less harsh laboratory conditions (e.g. a few minutes at 25°C).

And above all, a much wider variety of polymers is available, thus multiplying the chances that an active substance will find its appropriate biodegradable excipient. These promising results have given rise to the filing of two patents.

An unquestio ned advance in the daily routine of patients, this technique might also be popular with the major pharmaceutical companies, as it would constitute an added value for traditional drugs, which could be presented in a sustained-release formulation.


Related medicine news :

1. Hearing Problems Of Middle Age Are Affecting The Younger Generation
2. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
3. Newer Generation Sleeping Pills Lack Superior Performance
4. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
5. Moles Among The Older Generation May Be Dangerous
6. Leptin, The Next Generation Antidepressant?
7. Generation Scotland To Examine Relation Between Lifestyle, Genetics and Health
8. Baby Gloom: ‘Baby Gap’ Generation Signals Babies’ Days Ot!
9. Researchers Aim To Develop Next Generation Of Surgical Robots
10. New Generation Teenagers Addiction to Prescription Drugs
11. Take Third Generation Oral Contraceptives Off the Shelves-consumer Group Insists
Post Your Comments:

(Date:12/1/2015)... ... , ... It’s official: Tattoo taboo is a thing of the past. One ... (a whopping one in three aged 18 to 25 is inked). As tattoos transition ... ink. In fact, RealSelf , the world’s largest community for learning and sharing ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... technicians must mark the film for accurate interpretation by the radiologist. The marking ... an inventor from Sacramento, Calif., has found a way to alleviate this problem. ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the Field for Effective Post-Affiliation Integration ,” addresses a main “pain point” for ... deliver the anticipated results, once a deal is signed. This quick-read guidance ...
(Date:12/1/2015)... China (PRWEB) , ... December 01, 2015 , ... Nurotron ... result in its largest order to date. , The order will be from ... systems. Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Sweden , December 1, 2015 ... Cancer Study Group (IBCSG, Bern ) and ... to be part of a state of the art trial, ... --> --> The study, ... treated with anti-hormonal therapy in combination with palbociclib, a cancer ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical Device ... 22 nd April 2016. --> --> ... --> -->   --> --> ... population and the government back up, the Medical Device is one of the ... . With the aging population and the government back up, the Medical ...
Breaking Medicine Technology: